| Ms Mary Conwall Reed, CNM | |
|
2000 Waverly Pkwy, Opelika, AL 36801-4739 | |
| (334) 528-5808 | |
| (334) 528-2161 |
| Full Name | Ms Mary Conwall Reed |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 2000 Waverly Pkwy, Opelika, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689764193 | NPI | - | NPPES |
| 007790686 541581185 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 0024151541 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Mary Conwall Reed, CNM 2000 Pepperell Pkwy, Opelika, AL 36801-5452 Ph: (334) 528-5808 | Ms Mary Conwall Reed, CNM 2000 Waverly Pkwy, Opelika, AL 36801-4739 Ph: (334) 528-5808 |
News Archive
Edison Pharmaceuticals, Inc. announced today the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for treatment of inherited mitochondrial respiratory chain diseases.
Branch retinal vein occlusion - blockage of the blood vessels that channel blood from the retina - is a common eye disease. A type of blood clot in the eye, the disease causes reduced vision, and people with the disease also typically have an increased risk of hypertension, diabetes and other serious conditions. A young scientist from the University of Copenhagen has made a significant contribution to finding the cause of the disease.
Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
For adults with diabetes, managing the disease is a day-in, day-out effort to control the factors that affect blood sugar levels.
› Verified 2 days ago